Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
122 pending office actions • 58 clients • 113 examiners • 64 art units • 0 of 122 (0%) have an AI response strategy ready
PABST PATENT GROUP LLP operates in the Biotechnology & Pharmaceuticals technology area, having handled 3803 career applications. The firm has achieved a resolved allowance rate of 76.24 percent.
The firm currently has 102 pending office actions and averages 4.67 office actions per allowance. This average of 4.67 indicates a persistent prosecution strategy for its 3803 career applications.
Based on the USPTO statutory response window for each pending office action. 38 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 38 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 17 (14%) |
| §103 only | 28 (23%) |
| §102 only | 1 (1%) |
| §112 only | 9 (7%) |
| Double-patenting only | 2 (2%) |
| Double-patenting + other | 14 (11%) |
| Multi-statute (no §101) | 50 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.6% |
| DONOHUE, SEAN R | 2 | 41.4% | +21.0% |
| MATALKAH, FATIMAH KHALAF | 2 | 54.8% | +28.6% |
| MIKNIS, ZACHARY J | 2 | 68.6% | +32.2% |
| SVEIVEN, MICHAEL CAMERON | 2 | 37.5% | +47.9% |
| GIAMMONA, FRANCESCA FILIPPA | 2 | 37.5% | +57.4% |
| STEINKE, SEAN JAMES | 2 | 12.5% | +42.9% |
| WANG, RUIXUE | 2 | 57.4% | +17.8% |
| SINGH, ANOOP KUMAR | 2 | 43.0% | +67.6% |
| BALAJ, ANTHONY MICHAEL | 1 | 30.6% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 147d overdue |
| 17777011 | SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES | SVEIVEN, MICHAEL CAMERON | 80d overdue |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 59d overdue |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | WANG, RUIXUE | 31d overdue |
| 17641516 | NANOPARTICLES FOR SELECTIVE TISSUE OR CELLULAR UPTAKE | LAZARO, DOMINIC | 30d overdue |
| 18269114 | A METHOD | WOLLSCHLAGER, JEFFREY MICHAEL | 11d overdue |
| 18490443 | USE OF A SPLIT dCAS FUSION PROTEIN SYSTEM FOR EPIGENETIC EDITING | PHILIPOSE, HANNAH SARAH | 2d overdue |
| 18000425 | SSTR-2 Binding Chimeric Antigen Receptors | DRISCOLL, MAUREEN VARINA | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17777011 | SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES | SVEIVEN, MICHAEL CAMERON | 80d overdue |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | SINGH, ANOOP KUMAR | 59d overdue |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | WANG, RUIXUE | 31d overdue |
| 17259766 | COMPOSITIONS AND METHODS FOR REPROGRAMMING SKIN INTO INSULIN PRODUCING TISSUE | SINGH, ANOOP KUMAR | 8d overdue |
| 18248285 | METHODS AND MEANS FOR AMPLIFICATION-BASED QUANTIFICATION OF NUCLEIC ACIDS | GIAMMONA, FRANCESCA FILIPPA | 14d |
| 17517039 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | DONOHUE, SEAN R | 15d |
| 18179069 | ENTERAL CARBON MONOXIDE FOR THE PREVENTION AND TREATMENT OF OCULAR DISEASES | STEINKE, SEAN JAMES | 34d |
| 19314645 | SYSTEM AND METHOD FOR ALGORITHMIC DIAGNOSTICS FOR EFFICIENT PRESCRIPTION OF TREATMENTS FOR B-SNIP PSYCHOSIS BIOTYPES | BALAJ, ANTHONY MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1619 | 4 |
| 1631 | 4 |
| 1653 | 3 |
| 1638 | 3 |
| 1625 | 3 |
| 1678 | 3 |
| 1618 | 3 |
| 1635 | 3 |
| 1658 | 3 |
| 1677 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19314645 | SYSTEM AND METHOD FOR ALGORITHMIC DIAGNOSTICS FOR EFFICIENT PRESCRIPTION OF TREATMENTS FOR B-SNIP PSYCHOSIS BIOTYPES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | BALAJ, ANTHONY MICHAEL | 3682 | §101§103 | Non-Final OA | — | Pending | Aug 29, 2025 |
| 19023761 | HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF | Yale University | MAEWALL, SNIGDHA | DP | Non-Final OA | — | Pending | Jan 16, 2025 | |
| 18990707 | METHODS TO IDENTIFY A PRESENCE OR ABSENCE OF OBSTRUCTIVE SLEEP APNEA IN PATIENTS | Powell Mansfield, Inc. | PREMRAJ, CATHERINE C | §101 | Non-Final OA | — | Pending | Dec 20, 2024 | |
| 18990391 | NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | SONG, JIANFENG | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2024 | |
| 18905699 | SHAPEABLE SCAFFOLD MATERIAL AND USES THEREOF | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) | LIU, TRACY | §103§112DP | Non-Final OA | — | Pending | Oct 03, 2024 | |
| 18849428 | BIODEGRADABLE CONTROLLED RELEASE ANTIVIRAL AGENT IMPLANTS | Yale University | BURKE, MATTHEW RYAN | §103 | Non-Final OA | — | Pending | Sep 20, 2024 | |
| 18800902 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | Research Institute AT Nationwide Children’S Hospital | SABOKTAKIN, MARJAN | 3797 | §103 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18835557 | COMPOSITIONS | Imperial College Innovations Ltd. | WRIGHT, ERIC BRANDON | §101§102§112 | Non-Final OA | — | Pending | Aug 02, 2024 | |
| 18789224 | COMPOSITION COMPRISING A CROSS-LINKED POLYOL | Volumina Medical SA | AZPURU, CARLOS A | DP | Non-Final OA | — | Pending | Jul 30, 2024 | |
| 18833322 | RADIOSENSITIZING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | PIPIC, ALMA | 1617 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18779564 | TREATMENT OF INCLUSION BODY MYOSITIS WITH ADIPOSE-DERIVED REGENERATIVE CELLS | UNIVERSITY OF KANSAS | MELLER, MICHAEL V | §102§103 | Non-Final OA | — | Pending | Jul 22, 2024 | |
| 18772004 | MUNITIONS AND ORDNANCE REMEDIATION BLANKET (MORB) AND METHODS OF USING SAME | MuniRem Environmental, LLC | HAYES, BRET C | 3641 | §112DP | Final Rejection | — | Pending | Jul 12, 2024 |
| 18718628 | CONCENTRATED PREMIX FOR A PLANT-BASED FROZEN CONFECTION | Magnum Icc US, LLC | WATTS, JENNA A | 1791 | §103 | Final Rejection | — | Pending | Jun 11, 2024 |
| 18661820 | BACTERIOPHAGE-DERIVED NANOPORE SENSORS | Oxford Nanopore Technologies PLC | BALL, JOHN C | 1795 | §103 | Final Rejection | 46d overdue | Pending | May 13, 2024 |
| 18653590 | OCULAR ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | The University of Hong Kong | IANNUZO, NATALIE NMN | 1653 | §103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18653847 | ONCOLYTIC VIRUSES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18703995 | METHODS OF TREATING CANCER | Fusion Pharmaceuticals Inc. | MOSHER, ERIC PARKER | §103§112DP | Non-Final OA | — | Pending | Apr 23, 2024 | |
| 18692729 | NANOPARTICLE SURFACE TOPOGRAPHY MODIFIED WITH BOTTLEBRUSH BLOCK COPOLYMERS | Yale University | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18600046 | MODIFIED O-METHYLTRANSFERASES USEFUL FOR PRODUCTION OF O-METHYLATED PHENOLIC NATURAL PRODUCTS | The University of Hong Kong | HUTSON, RICHARD G | 1652 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690230 | IODIDE NANOPARTICLES AND COMPOSITIONS OF METHODS OF USE THEREOF | The University of North Carolina at Chapel Hill | DONOHUE, SEAN R | §102§103Other | Non-Final OA | — | Pending | Mar 07, 2024 | |
| 18690140 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | D&D Pharmatech Inc. | NIEBAUER, RONALD T | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18688178 | ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF | Centre For Virology, Vaccinology And Therapeutics Limited | MATALKAH, FATIMAH KHALAF | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 | |
| 18686711 | GLP-1R AGONISTS FOR USE IN A TREATMENT OF NEUROLOGIAL IMPAIRMENT ASSOCIATED WITH VIRAL INFECTION | Neuraly, Inc. | MIKNIS, ZACHARY J | §102§103§112DP | Non-Final OA | — | Pending | Feb 26, 2024 | |
| 18441806 | ENGINEERED GUIDE RNA SCAFFOLDS AND METHODS THEROF FOR ENHANCED GENOME EDITING | Centre For Oncology And Immunology Limited | GROOMS, TIFFANY NICOLE | §101§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 | |
| 18682594 | Pharmaceutical Compositions Comprising Dendritic Nanocarriers and Cannabis Active Agents | Dendropharm GmbH | CHI, AMANDA LYNN | 1613 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18681561 | FIBRINOGEN COMPOSITIONS AND METHODS OF PREPARATION | Biotest AG | GOTFREDSON, GAREN | 1619 | §103 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18681271 | COMPOSITIONS AND METHODS FOR FAST MULTIPLEXED SCREENING AND MONITORING OF NPM1 MUTATIONS | The University of Hong Kong | KAPUSHOC, STEPHEN THOMAS | 1683 | §102§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18291999 | GENE SIGNATURE PREDICTING TERTIARY LYMPHOID STRUCTURES CONTAINING B CELLS | H. Lee Moffitt Cancer Center and Research Institute, Inc. | HAUK TEODORO, PRICILA NMN | 1645 | §101§103 | Final Rejection | — | Pending | Jan 25, 2024 |
| 18577631 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | BELL, SARA ELIZABETH | 1625 | §102§103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18542277 | DNA METHYLATION BIOMARKERS FOR CANCER DIAGNOSING | Arizona Board of Regents | GOLDBERG, JEANINE ANNE | 1682 | §102§112Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18538932 | SEQUENTIAL TRANSARTERIAL CHEMOEMBOLIZATION, STEREOTACTIC BODY RADIOTHERAPY, AND IMMUNOTHERAPY (START-FIT) FOR HEPATOCELLULAR CARCINOMA | The University of Hong Kong | MIDDLETON, DANAYA L | 4100 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18569361 | ROS-RESPONSIVE CAPTOPRIL-CINNAMALDEHYDE PRODRUGS AND COMPOSITIONS AND METHODS THEREOF | The University of Hong Kong | CHANDRAKUMAR, NIZAL S | 1625 | §102§112Other | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18566491 | FIBROSIS BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE | The University of Hong Kong | SVEIVEN, MICHAEL CAMERON | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18565831 | METHODS OF USING ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T CELLS | Regents Of The University Of Minnesota | HAM, JIEUN | §103§112DP | Non-Final OA | — | Pending | Nov 30, 2023 | |
| 18565805 | CAR-T CELL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER | H. Lee Moffitt Cancer Center and Research Institute, Inc. | LIU, SUE XU | §102§103§112Other | Non-Final OA | — | Pending | Nov 30, 2023 | |
| 18521615 | POLYMER COATED IRON OXIDE NANORODS AND METHODS OF MAKING AND USE THEREOF | 5M Biomed, LLC | BAEK, JONGHWAN NMN | 1618 | §102§103§112DP | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18563581 | IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY | H. Lee Moffitt Cancer Center and Research Institute, Inc. | AEDER, SEAN E | §112 | Final Rejection | — | Pending | Nov 22, 2023 | |
| 18563286 | THERMALLY ACTIVATED DELAYED FLUORESCENT PALLADIUM (II) COMPLEXES FOR OLED APPLICATIONS | Hong Kong Quantum AI Lab Limited | KOLLIAS, ALEXANDER C | §102§103§112 | Non-Final OA | — | Pending | Nov 21, 2023 | |
| 18506847 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS | BM Pharma Consulting Pty Ltd. | BURKETT, DANIEL JOHN | 1624 | §112 | Final Rejection | — | Pending | Nov 10, 2023 |
| 18506988 | A-FABP NEUTRALIZING MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF | Shenzhen Institute Of Advanced Technology, Chinese Academy Of Sciences | MCCOLLUM, ANDREA K | 1674 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18560347 | COMPOSITIONS AND METHODS OF TARGETING THE PAX6 SIGNALING PATHWAY TO REDUCE FORMATION OF AMYLOID BETA PLAQUES AND NEUROFIBRILLARY TANGLES | The University of Hong Kong | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18558943 | SEQUENCE-DEFINED POLYMERS WITH ONE OR MORE AZIDES, METHODS OF MAKING, AND METHODS OF USE THEREOF | Yale University | SPANGLER, JOSEPH RANKIN | 1656 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18490443 | USE OF A SPLIT dCAS FUSION PROTEIN SYSTEM FOR EPIGENETIC EDITING | The Regents of the University of California | PHILIPOSE, HANNAH SARAH | 1631 | §103§112 | Non-Final OA | 2d overdue | Pending | Oct 19, 2023 |
| 18554144 | EFFECT OF GHRH ANTAGONISTS IN DIABETES AND OBESITY | The United States Government AS Represented By The Dept. Of Veterans Affairs | BUCCINI, MICHELLE CALLAHAN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18375697 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS | Ohio State Innovation Foundation | COUGHLIN, MATTHEW P | 1626 | §103 | Final Rejection | 29d overdue | Pending | Oct 02, 2023 |
| 18551025 | AN APPARATUS AND ASSOCIATED METHODS FOR THERMAL CYCLING | Bg Research Ltd. | YOUNG, NATASHA E | 3763 | §112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18466622 | METAL-ASSISTED MULTI-RESONANCE THERMALLY-ACTIVATED DELAYED-FLUORESCENCE EMITTERS FOR OLED APPLICATIONS | Hong Kong Quantum AI Lab Limited | NGUYEN, VU ANH | §102§112 | Non-Final OA | — | Pending | Sep 13, 2023 | |
| 18464817 | Dental Care Products Comprising Stannous Flouride | Credentis AG | JAUHARI, SACHI | 1654 | §103 | Final Rejection | 26d | Pending | Sep 11, 2023 |
| 18549950 | CHIPS AND METHODS | Imperial College Innovations Ltd. | KIDWELL, KAITLYN ELIZABETH | 2877 | §103 | Non-Final OA | 85d overdue | Pending | Sep 11, 2023 |
| 18548206 | R-T-B MAGNET AND PREPARATION METHOD THEREFOR | Fujian Golden Dragon Rare-Earth Co., Ltd. | MCGUTHRY BANKS, TIMA MICHELE | 1733 | §112 | Final Rejection | — | Pending | Aug 28, 2023 |
| 18546895 | ANTI-VIRAL PEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF | Centre For Virology, Vaccinology And Therapeutics Limited | KOMATSU, LI N | 1658 | §101§102§112DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18546720 | CANNABIDIOL FOR TREATING NEURODEGENERATIVE DISEASES | Augusta University Research Institute, Inc. | JAVANMARD, SAHAR | 1622 | §102§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18264695 | CELL NICHE ENGINEERING PLATFORM, MULTIPLEXED BIOCHIPS RESULTING THEREFROM AND METHODS OF USE THEREOF | The University of Hong Kong | HASSAN, LIBAN M | 1799 | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2023 |
| 18364503 | ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30 | The Trustees of Dartmouth College | FAUST, AMBER KATHLEEN | 1643 | §102§103§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18353717 | DINUCLEAR PLATINUM COMPLEXES FOR OLED APPLICATION | Hong Kong Quantum AI Lab Limited | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | 4d overdue | Pending | Jul 17, 2023 |
| 18350402 | COMPOSITIONS OF CASPASE INHIBITORS AND METHODS OF USE THEREOF | Centre For Virology, Vaccinology And Therapeutics Limited | MIKNIS, ZACHARY J | 1658 | §102§112 | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18346483 | SYSTEMS AND REAGENTS FOR DETECTION OF FREE MONOCLONAL IMMUNOGLOBULIN LIGHT CHAINS IN BIOLOGICAL SAMPLES | Augusta University Research Institute, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 03, 2023 |
| 18345934 | STEM CELL COMPOSITIONS FOR CULTURING CORONAVIRUSES AND METHODS OF MAKING AND USING THEREOF | Centre For Translational Stem Cell Biology Limited | ALAM, DANYAL HASSAN | 1672 | §101§103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18345284 | SUPER-HIGH-PERMEANCE THIN-FILM COMPOSITE NANOFILTRATION MEMBRANE INCORPORATING SILK NANOFIBER INTERLAYER | The University of Hong Kong | HUANG, RYAN | 1777 | §102§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18269114 | A METHOD | ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE | WOLLSCHLAGER, JEFFREY MICHAEL | 1742 | §103§112 | Final Rejection | 11d overdue | Pending | Jun 22, 2023 |
| 18258870 | A DEVICE AND A METHOD | Imperial College Innovations Limited | WORRELL, KEVIN | 1789 | §102§103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18267931 | COMPOSITIONS IMMUNOGENIC AGAINST INFLUENZA AND SARS CORONAVIRUS 2, METHODS OF MAKING AND USING THEREOF | VERSITECH LIMITED | LI, BAO Q | 1671 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18254669 | LENTIVIRAL VECTOR TECHNOLOGY FOR INNER EAR GENE THERAPY | Medizinische Hochschule Hannover | YU, DELPHINUS DOU YI | 1636 | §103 | Final Rejection | — | Pending | May 26, 2023 |
| 18253793 | INHIBITION OF KIR2DL2 FOR THE ENHANCEMENT OF ADOPTIVE IMMUNOTHERAPIES | H. Lee Moffitt Cancer Center and Research Institute, Inc. | MCLEOD, AFRICA MHAIRIE | 1635 | §101§112 | Non-Final OA | — | Pending | May 22, 2023 |
| 18253891 | COMPOSITIONS AND METHODS FOR BLOCKING NEUROPILIN RECEPTOR 1 FOR THE TREATMENT OF PAIN AND PREVENTION OF VIRAL ENTRY | Arizona Board of Regents | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103 | Final Rejection | 19d | Pending | May 22, 2023 |
| 18251374 | TRANSFERABLE TYPE I-F CRISPR-CAS GENOME EDITING SYSTEM | The University of Hong Kong | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Final Rejection | — | Pending | May 01, 2023 |
| 18251078 | COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY LUNG DISEASES | Arizona Board of Regents | BEANE, RANDALL L | 1654 | §102§112 | Non-Final OA | 55d | Pending | Apr 28, 2023 |
| 18249926 | COMPOSITIONS OF ANTI-VIRAL PEPTIDES AND/OR COMPOUNDS AND METHODS OF USE THEREOF | The University of Hong Kong | KATAKAM, SUDHAKAR | 1658 | §112DP | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18249806 | METHOD AND KIT FOR TESTING IMMUNOMODULATORY POTENCY OF IMMUNOGLOBULIN COMPOSITIONS, e.g. FOR TREATMENT OF COVID 19 | Biotest AG | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Final Rejection | — | Pending | Apr 20, 2023 |
| 18248285 | METHODS AND MEANS FOR AMPLIFICATION-BASED QUANTIFICATION OF NUCLEIC ACIDS | Imperial College Innovations Limited | GIAMMONA, FRANCESCA FILIPPA | 1681 | §101§103 | Final Rejection | 14d | Pending | Apr 07, 2023 |
| 18030801 | METHODS AND AGENTS FOR TREATING, PREVENTING, DIAGNOSING, AND EVALUATING THERAPY FOR FIBROTIC, AUTOIMMUNE, AND INFLAMMATORY CONDITIONS | The Trustees of Dartmouth College | MYERS, CARLA J | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 07, 2023 |
| 18295454 | CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE | The Trustees of Dartmouth College | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Final Rejection | — | Pending | Apr 04, 2023 |
| 18185164 | CXCL14 AS PREDICTIVE BIOMARKER FOR ACUTE LIVER FAILURE AND DEATH | UNIVERSITY OF KANSAS | HOFFMAN, ALEXANDER JOSEPH | 1677 | §101§103 | Final Rejection | — | Pending | Mar 16, 2023 |
| 18179069 | ENTERAL CARBON MONOXIDE FOR THE PREVENTION AND TREATMENT OF OCULAR DISEASES | Hillhurst Biopharmaceuticals, Inc. | STEINKE, SEAN JAMES | 1619 | §102§103Other | Final Rejection | 34d | Pending | Mar 06, 2023 |
| 18170296 | COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | The University of Hong Kong | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2023 |
| 18169695 | HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING | The General Hospital Corporation | STEVENS, MARK V | 1613 | §103§112 | Final Rejection | 14d | Pending | Feb 15, 2023 |
| 18041656 | VALVELESS DEVICES FOR PULSATILE FLUID FLOW | VANDERBILT UNIVERSITY | PEKARSKAYA, LILYA | 3746 | §103§112 | Final Rejection | — | Pending | Feb 14, 2023 |
| 18041542 | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATING AUTOIMMUNITY | Regents Of The University Of Minnesota | BELYAVSKYI, MICHAIL A | 1644 | §102§103DP | Final Rejection | — | Pending | Feb 13, 2023 |
| 18005830 | PROCESS FOR CATALYTIC UPCYCLING OF HYDROCARBON POLYMERS TO ALKYLAROMATIC COMPOUNDS | The Regents of the University of California | BOYER, RANDY | 1771 | §103§112 | Non-Final OA | — | Pending | Jan 17, 2023 |
| 18005016 | FORMATE-INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | Imperial College Innovations Ltd. | RYAN, DOUGLAS CHARLES | 1635 | §102§112 | Final Rejection | 12d | Pending | Jan 10, 2023 |
| 18000425 | SSTR-2 Binding Chimeric Antigen Receptors | UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO | DRISCOLL, MAUREEN VARINA | 1642 | §102§103 | Non-Final OA | 9d | Pending | Dec 01, 2022 |
| 18000075 | GENE FOR REGULATING BRANCH NUMBERS OF SOYBEAN AND USE THEREOF | Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences | CHATTERJEE, JAYANTA | 1662 | §103 | Final Rejection | — | Pending | Nov 28, 2022 |
| 18057632 | d10 METAL CARBENE COMPLEXES FOR OLED APPLICATIONS | Hong Kong Quantum AI Lab Limited | KERSHNER, DYLAN CLAY | 1786 | §103 | Final Rejection | 36d | Pending | Nov 21, 2022 |
| 17998790 | CANNABIDIOL AS A THERAPEUTIC MODALITY FOR COVID-19 | Augusta University Research Institute, Inc. | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103 | Final Rejection | 23d | Pending | Nov 14, 2022 |
| 17996287 | IDENTIFICATION OF NSP1 GENE AS TARGET OF SARS-COV-2 REAL-TIME RT-PCR USING NANOPORE WHOLE GENOME SEQUENCING | The University of Hong Kong | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | — | Pending | Oct 14, 2022 |
| 17913425 | FROZEN CONFECTION | Magnum Icc US, LLC | MERRIAM, ANDREW E | 1791 | §103 | Final Rejection | — | Pending | Sep 21, 2022 |
| 17797503 | METHODS FOR DETECTING PRIMARY IMMUNODEFICIENCY | Immunosis Pty Ltd. | STUBBS, JOHN THOMAS | 1686 | §101§103§112 | Non-Final OA | — | Pending | Aug 04, 2022 |
| 17868214 | BINUCLEAR GOLD(I) COMPOUNDS FOR PHOTOCATALYSIS APPLICATIONS | Laboratory For Synthetic Chemistry And Chemical Biology Limited | PIRO, NICHOLAS ANTHONY | 1738 | §102 | Non-Final OA | — | Pending | Jul 19, 2022 |
| 17850720 | COMPOSITIONS AND METHODS FOR OPTOCHEMICAL CONTROL OF MTOR SIGNALING AND MTOR-DEPENDENT AUTOPHAGY | The University of Hong Kong | NOTTINGHAM, KYLE GREGORY | 1621 | §103§112 | Final Rejection | — | Pending | Jun 27, 2022 |
| 17757475 | Systems and Methods for Producing Efficacious Regulatory T Cells | H. Lee Moffitt Cancer Center and Research Institute, Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103 | Non-Final OA | — | Pending | Jun 16, 2022 |
| 17782252 | ADOPTIVE CELL THERAPY WITH ZBTB20 SUPPRESSION | The Trustees of Dartmouth College | MATALKAH, FATIMAH KHALAF | 1638 | §112 | Final Rejection | — | Pending | Jun 03, 2022 |
| 17756138 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | H. Lee Moffitt Cancer Center and Research Institute, Inc. | VIVLEMORE, TRACY ANN | 1638 | §112 | Non-Final OA | 44d overdue | Pending | May 18, 2022 |
| 17777011 | SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES | Arizona Board of Regents | SVEIVEN, MICHAEL CAMERON | 1678 | §103§112Other | Non-Final OA | 80d overdue | Pending | May 13, 2022 |
| 17735271 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | Centre For Oncology And Immunology Limited | MCANANY, JOHN D | 1625 | §102§103§112 | Non-Final OA | 12d | Pending | May 03, 2022 |
| 17734826 | COMPOSITE FILAMENT FOR 3D PRINTING OF RESORBABLE BONE SCAFFOLDS | Arizona Board of Regents | BAHENA, CHRISTIE L. | 3774 | §103 | Non-Final OA | 28d | Pending | May 02, 2022 |
| 17729584 | SURGERY DEVICE WITH PATIENT-SPECIFIC FIBULA MALLEOLUS CAP | The University of Hong Kong | HU, ANN M | 3774 | §102§103 | Final Rejection | 72d | Pending | Apr 26, 2022 |
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | Salk Institute For Biological Studies | KIM, TAEYOON | 1631 | §102§103 | Final Rejection | 147d overdue | Pending | Apr 15, 2022 |
| 17762931 | METHOD FOR ISOLATING EXTRACELLULAR VESICLES | Imperial College Innovations Limited | ZINGARELLI, SANDRA | 1653 | §103§112 | Non-Final OA | 34d | Pending | Mar 23, 2022 |
| 17641516 | NANOPARTICLES FOR SELECTIVE TISSUE OR CELLULAR UPTAKE | Yale University | LAZARO, DOMINIC | 1611 | §103§112 | Non-Final OA | 30d overdue | Pending | Mar 09, 2022 |
| 17677676 | TOPICAL NEUROSTEROID FORMULATIONS | Arizona Board of Regents | STEINKE, SEAN JAMES | 1619 | §103§112DP | Final Rejection | — | Pending | Feb 22, 2022 |
| 17635111 | CHIMERIC ANTIGEN RECEPTORS FOR TREATING MYELOID MALIGNANCIES | Regents Of The University Of Minnesota | BERHANE, SELAM | 1675 | §103§112Other | Final Rejection | 39d | Pending | Feb 14, 2022 |
| 17635119 | ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS | H. Lee Moffitt Cancer Center and Research Institute, Inc. | LUNDE, GRACE HENRY | 1641 | §103§112DP | Non-Final OA | 184d overdue | Pending | Feb 14, 2022 |
| 17669059 | THREE-DIMENSIONAL POROUS HYBRID SCAFFOLD AND MANUFACTURE THEREOF | Nanyang Technological University | MARTIN, PAUL C | 1653 | §103§112 | Non-Final OA | 78d | Pending | Feb 10, 2022 |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | H. Lee Moffitt Cancer Center and Research Institute, Inc. | SINGH, ANOOP KUMAR | 1632 | §103§112 | Final Rejection | 59d overdue | Pending | Jan 26, 2022 |
| 17626954 | R-Fe-B SINTERED MAGNET AND GRAIN BOUNDARY DIFFUSION TREATMENT METHOD THEREOF | Golden Dragon Rare-Earth Innovation Technology (Xiamen) Co., Ltd. | POLLOCK, AUSTIN M | 1738 | §103 | Non-Final OA | 54d | Pending | Jan 13, 2022 |
| 17619116 | DNA METHYLATION BIOMARKERS FOR CANCER DIAGNOSING AND TREATMENT | Arizona Board of Regents | GIAMMONA, FRANCESCA FILIPPA | 1681 | §101§102§103§112DP | Final Rejection | — | Pending | Dec 14, 2021 |
| 17615504 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | D&D Pharmatech Inc. | JARRELL, NOBLE E | 1699 | §112DP | Final Rejection | 56d | Pending | Nov 30, 2021 |
| 17614936 | THERAPEUTIC T-CELLS WITH MODIFIED EXPRESSION OF T-BET, EOMES, AND c-MYB TRANSCRIPTION FACTORS | H. Lee Moffitt Cancer Center and Research Institute, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Non-Final OA | — | Pending | Nov 29, 2021 |
| 17610892 | SENSORS AND METHODS USING ELECTROCHEMILUMINESCENCE OF METAL NANOCLUSTERS | Georgia State University Research Foundation, Inc. | DICKINSON, PAUL W | 1618 | §103§112 | Final Rejection | 12d | Pending | Nov 12, 2021 |
| 17517039 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | Centre For Probe Development And Commercialization | DONOHUE, SEAN R | 1618 | §103Other | Final Rejection | 15d | Pending | Nov 02, 2021 |
| 17434909 | REACTIVE ELECTROCHEMICAL MEMBRANE SYSTEM AND METHODS OF MAKING AND USING | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | JEBUTU, MOFOLUWASO SIMILOLUWA | 1795 | §102§103 | Non-Final OA | — | Pending | Aug 30, 2021 |
| 17424109 | SALT NANOPARTICLES AND COMPOSITIONS AND METHODS OF USE THEREOF | The University of North Carolina at Chapel Hill | NGUYEN, NGOC-ANH THI | 1615 | §103 | Non-Final OA | — | Pending | Jul 19, 2021 |
| 17284284 | EXTRACELLULAR VESICLES FOR TARGETED THERAPIES AGAINST MYELOID-DERIVED SUPPRESSOR CELLS | Ohio State Innovation Foundation | GUSTILO, ESTELLA M | 1646 | §101§102§103§112 | Final Rejection | — | Pending | Apr 09, 2021 |
| 17281411 | TLR9-TARGETED THERAPEUTICS | Fulgent Pharma LLC | TRAN, CHRISTINA L | 1637 | §103 | Non-Final OA | 19d overdue | Pending | Mar 30, 2021 |
| 17269968 | TREATMENT OF FLAVIVIRUS INFECTIONS IN HUMANS USING MUS MUSCULUS RESISTANT 2'-5' OLIGOADENYLATE SYNTHETASE 1B | Georgia Tech Research Corporation | DUNSTON, JENNIFER ANN | 1637 | §103 | Final Rejection | 53d overdue | Pending | Feb 19, 2021 |
| 17265751 | ORAL FORMULATIONS WITH INCREASED UPTAKE | Brown University | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Non-Final OA | — | Pending | Feb 03, 2021 |
| 17265756 | COMPOSITIONS AND METHODS FOR DETECTION AND IMAGING OF AMYLOID FIBRILS, AMYLOID PLAQUES, RNA, AND NUCLEOLI | The University of Hong Kong | NGUYEN, NAM P | 1678 | §102§103§112DP | Final Rejection | 43d overdue | Pending | Feb 03, 2021 |
| 17264673 | A JOINT | Ip2Ipo Innovations Limited | SHARPLESS, CHRISTEN ALICIA | 3795 | §102§103 | Non-Final OA | — | Pending | Jan 29, 2021 |
| 17259766 | COMPOSITIONS AND METHODS FOR REPROGRAMMING SKIN INTO INSULIN PRODUCING TISSUE | Ohio State Innovation Foundation | SINGH, ANOOP KUMAR | 1632 | §103 | Non-Final OA | 8d overdue | Pending | Jan 12, 2021 |
| 17059965 | MATURE AIRWAY ORGANOIDS, METHODS OF MAKING AND USES THEREOF | Koninklijke Nederlandse Akademie Van Wetenschappen | GOUGH, TIFFANY MAUREEN | 1651 | §112 | Final Rejection | — | Pending | Nov 30, 2020 |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | The University of Hong Kong | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | 31d overdue | Pending | Oct 16, 2020 |
| 16619433 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. | CRAIGO, BAHAR ALAWI | 1699 | §112Other | Non-Final OA | 5d | Pending | Dec 04, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial